Excessive demands on the protein-folding capacity of the endoplasmic reticulum (ER) cause irremediable ER stress and contribute to cell loss in a number of cell degenerative diseases, including type 2 diabetes and neurodegeneration 1,2 . The signals communicating catastrophic ER damage to the mitochondrial apoptotic machinery remain poorly understood 3-6 . We used a biochemical approach to purify a cytosolic activity induced by ER stress that causes release of cytochrome c from isolated mitochondria. We discovered that the principal component of the purified pro-apoptotic activity is the proto-oncoprotein CRK (CT10-regulated kinase), an adaptor protein with no known catalytic activity 7 . Crk −/− cells are strongly resistant to ER-stress-induced apoptosis. Moreover, CRK is cleaved in response to ER stress to generate an amino-terminal M r ∼14K fragment with greatly enhanced cytotoxic potential. We identified a putative BH3 (BCL2 homology 3) domain within this N-terminal CRK fragment, which sensitizes isolated mitochondria to cytochrome c release and when mutated significantly reduces the apoptotic activity of CRK in vivo. Together these results identify CRK as a pro-apoptotic protein that signals irremediable ER stress to the mitochondrial execution machinery.
and PUMA have previously been implicated in ER-stress-induced death 14, 15 ; however, cells deficient in one or more of these proteins are not completely resistant to this form of apoptosis [16] [17] [18] . Therefore, it is highly probable that additional proteins that communicate ER stress to the mitochondrial apoptotic machinery remain to be discovered. To pursue this possibility, we took an unbiased biochemical approach to purify the main ER-stress-induced cytosolic pro-apoptotic activity.
Given their strong resistance to ER-stress-induced apoptosis 16, 17 , we reasoned that the Bax −/− Bak −/− mouse embryonic fibroblasts (MEFs) present a unique and powerful tool to trap and identify pre-mitochondrial apoptotic signals activated by ER stress. Therefore, we challenged SV40-transformed Bax −/− Bak −/− MEFs with the pharmacological agent brefeldin A (BFA), which blocks ER-Golgi protein transport, to induce irremediable ER stress and initiate the pre-mitochondrial apoptotic program. We prepared cytosolic extracts (S100) from untreated or BFA-treated Bax −/− Bak −/− MEFs, then incubated isolated Jurkat mitochondria with these extracts, and measured the amount of mitochondrial cytochrome c released as a readout for pro-apoptotic activity. The S100 of BFA-treated Bax −/− Bak −/− cells triggers the release of ∼90% of the total intra-mitochondrial cytochrome c in a BAX/BAK-dependent manner 15 , whereas the S100 fraction from untreated Bax −/− Bak −/− MEFs induces negligible (<5%) cytochrome c release (Fig. 1a) . Thus, ER stress induces a cytosolic activity capable of releasing mitochondrial cytochrome c, which we have termed cytochrome-c-releasing activity (CcRA). We previously found that proteolytically active BID (truncated (t)BID) is responsible for a portion of this CcRA (∼30%), but that most CcRA remains intact in BFA-treated Bid −/− S100 (ref. 15) . Therefore, we designed and carried out a biochemical purification strategy to isolate additional CcRA factors in the BFA-treated Bax −/− Bak −/− S100 (Fig. 1b) . The CcRA-containing fractions from the final step (Mono Q gradient; Fig. 1c ) of the purification scheme did not contain detectable amounts of any known BH3-only protein by immunoblotting (data not shown), and so were analysed by matrix-assisted laser desorption/ionization mass spectrometry (Fig. 1c) . CRK was the highest-confidence protein identified by mass spectrometry in the active fractions, with approximately 25% of the total sequence represented in six tryptic peptides (Supplementary Table S1 ). Crk encodes two splice isoforms, CRKI (relative molecular mass 28,000 (M r 28K)) and CRKII (M r 38K; ref. 7) , which have previously been recognized as adaptor components in multi-protein complexes involved in cell morphology, movement, proliferation and differentiation 19 . CRKI and CRKII share a common SRC homology 2 (SH2) domain and SH3 domain, and CRKII contains an additional carboxy-terminal SH3 domain 19 ( Fig. 1d) . As the peptides detected by mass spectrometry are common to both CRKI and CRKII, this information did not differentiate which isoform is present in the analysed fractions (Supplementary Table S1 ).
To determine whether CRK plays a role in ER-stress-induced apoptosis in cells, we challenged Crk −/− and wild-type matched MEFs with BFA or tunicamycin, an ER stress agent that specifically inhibits N -linked glycosylation. As previously reported, these Crk −/− MEFs are derived from genetically engineered embryos that fail to express either CRKI or CRKII (ref. 20 ; Fig. 2a) . Notably, S100 from BFA-treated Crk −/− MEFs has a significantly decreased level of CcRA when compared with that from BFA-treated wild-type MEFs (Fig. 2b) , indicating that CRK is required for most of the ER-stress-induced apoptotic signal. In addition, Crk −/− MEFs are strikingly resistant to ER-stress-induced apoptosis, but are as sensitive as wild-type MEFs to staurosporine, a pan-kinase inhibitor known to activate the mitochondrial apoptotic pathway independently of ER stress, thereby confirming the pro-apoptotic role of CRK specifically in the ER-stress-induced apoptotic pathway, rather than generally from other intrinsic stresses (Fig. 2c,d ).
To investigate which CRK isoform is necessary for ER-stress-induced apoptosis, we reconstituted Crk −/− MEFs by transient transfection with expression constructs encoding either CRKI or CRKII and evaluated their sensitivity to ER-stress-induced apoptosis. Surprisingly, CRKI and CRKII are both able to independently rescue the sensitivity of Crk −/− MEFs to ER-stress-induced apoptosis, indicating that a sequence common to CRKI and CRKII is required for the apoptotic activity of CRK (Fig. 3a,b) . We next attempted to use retroviral vectors to establish stable cell lines of Crk −/− MEFs expressing either CRKI or CRKII. Whereas we had no difficulty recovering cells reconstituted with CRKII, all attempts to establish stable CRKI expression in Crk −/− MEFs were unsuccessful, indicating that CRKI may be inherently cytotoxic. Stable reconstitution of CRKII in Crk −/− MEFs restores sensitivity to ER stress agents, but does not affect the response to staurosporine (Fig. 3c-e) , recapitulating the transient expression results (Fig. 3a) . Moreover, stable overexpression of CRKII and transient overexpression of CRKI further sensitize wild-type MEFs to ER stress ( Fig. 3f-i) . Together, these data strongly indicate that CRK is a critical component of the ER-stress-induced apoptotic pathway. To explore its potential role in ER stress, we monitored Crk messenger RNA and protein following BFA treatment ( Supplementary  Fig. S1 ). We detected no changes in CrkI or CrkII mRNA transcript levels following ER stress ( Supplementary Fig. S1 ). However, we found that ER stress causes depletion of full-length CRKII ( Supplementary  Fig. S2 ). To determine whether the amount of CRKII is reduced in a specific subcellular compartment, we probed subcellular fractions from Bax −/− Bak −/− MEFs and found that CRKII is partially localized to the ER, mitochondria and cytosol (Fig. 4a) . Moreover, following ER stress, the amount of M r 38K ER-and cytosol-localized CRKII is reduced, whereas levels of the mitochondrion-localized full-length CRKII change very little (Fig. 4a) . Interestingly, we found that following ER stress, CRKII seems to be sequentially cleaved at least twice, resulting in several distinct fragments ( Fig. 4a and Supplementary Fig. S3 ). Proteolytic cleavage is a post-translational modification recognized to activate other known pro-apoptotic proteins, such as BID, but had not been described previously for CRK (refs 21-24) .
We examined whether CRKI also undergoes cleavage events following ER stress. Following ER stress, at least one CRKI-specific cleavage product is readily observed (Fig. 4b) . In addition, we observe depletion of full-length endogenous CRKI and CRKII in both wild-type and Bax −/− Bak −/− MEFs following BFA treatment (Fig. 4c ), indicating that their cleavage occurs upstream of the mitochondrial apoptotic pathway. Furthermore, the loss of full-length CRKI and CRKII occurs only when the level of ER stress rises to cytotoxic levels, and correlates with the initiation of ER-stress-induced apoptosis [25] [26] [27] [28] ( Supplementary Fig. S4 ). 
L E T T E R S
Crk In an attempt to determine the role of CRK cleavage in its apoptotic activity, we examined a small panel of protease inhibitors for their ability to block this event (data not shown). We found that the pancysteine protease inhibitor ZVAD-FMK prevents ER-stress-induced loss of full-length CRKI and CRKII and protects Bax −/− Bak −/− MEFs from the cytopathic effects of ER stress (Supplementary Fig. S5 ). We previously identified caspase-2 as a pre-mitochondrial cysteine protease activated by ER stress 10 . However, caspase-2 is poorly inhibited by ZVAD-FMK and in vitro experiments with recombinant caspase-2 do not result in CRK cleavage (data not shown). These data indicate that a previously unidentified ER-stress-activated cysteine protease is responsible for CRK cleavage.
To determine whether the observed ER-stress-induced cleavage of CRK is critical for its apoptotic activity, we individually mutated each potential cysteine protease cleavage site (aspartic acid) in the CRK sequence. When stably reconstituted into Crk −/− MEFs, CRKII D110A (Crk −/− + CRKII D110A ) was the only aspartic acid mutant unable to be cleaved in response to ER stress (Fig. 4d) . Furthermore, non-cleavable CRKII D110A is defective in restoring Crk −/− MEF sensitivity to ERstress-induced apoptosis (Fig. 4e,f) , indicating that this cleavage event is critical for its apoptotic activity. Cleavage at Asp 110 is predicted to produce one fragment of approximately M r 25K, which can be detected by a C-terminal-specific antibody (Fig. 4d) , and a second N-terminal fragment of M r ∼14K, which is undetectable using available antibodies. As both CRKI and CRKII restore Crk −/− sensitivity to ER stress, it is likely that the shared N-terminal fragment (M r ∼14 K) contains the critical domain for its apoptotic function. To examine this prediction, we transiently expressed the N-terminally Flag-tagged fragment (NF110) in the absence of ER stress (Fig. 4g) and measured the level of apoptosis. As predicted, NF110 is able to potently induce cell death independently of ER stress (Fig. 4h,i) . From these data, we conclude that CRK is cleaved following ER stress at Asp 110 to produce a pro-apoptotic fragment. Further studies will be necessary to identify the upstream protease and its connection to the unfolded protein response pathway.
To further investigate the mechanism by which CRK triggers cell death, we investigated whether CRK-induced apoptosis is a BAX/BAKdependent process. Transient overexpression of CRKI or CRKII triggers apoptosis in wild-type MEFs, but not Bax −/− Bak −/− MEFs, confirming that both isoforms signal upstream of the BAX/BAK-dependent mitochondrial apoptotic pathway (Fig. 5a-d) . Pro-apoptotic BH3-only proteins are the only known molecules capable of activating BAX and/or BAK either directly or by inhibiting anti-apoptotic BCL-2 family proteins 4, 13 . Through sequence analysis, we identified a putative BH3-like domain within CRK that contains a number of conserved amino acids present in several recognized BH3-only proteins (Fig. 5e ). This sequence is present in both Crk splice forms and is located within the common N-terminal 110-amino-acid pro-apoptotic fragment ( Figs 1d and 5e ). In support of our hypothesis that CRK contains a BH3-like domain, we determined that CRK is capable of binding a prototypical anti-apoptotic BCL-2 family protein (BCL-XL), a common feature of most BH3-only proteins. Following ER stress induction, transiently expressed Flag-CRKII co-immunoprecipitates with BCL-XL on Flag-specific agarose beads (Fig. 5f) .
To determine whether this sequence has BH3-like pro-apoptotic activity, we treated isolated Jurkat mitochondria with a synthetic CRK BH3 domain (amino acids 77-96) and measured cytochrome c release. There are two classes of BH3-only domains, those that sensitize or activate BAX/BAK-dependent mitochondrial apoptosis 29 . BH3 domains that directly 'activate' BAX and/or BAK at mitochondria, such as the BH3 domain of BID, are able to cause cytochrome c release from isolated mitochondria. In contrast, 'sensitizing' BH3 domains, such as the BH3 domains of BAD and BIK, sensitize isolated mitochondria to release cytochrome c in the presence of a second 'activating' BH3 domain. In vivo, sensitizer BH3-only proteins are thought to competitively bind anti-apoptotic proteins, releasing bound 'activating' BH3-only proteins to induce mitochondrial permeability. Although the CRK BH3 domain is unable to induce cytochrome c release alone, it significantly potentiates with low concentrations of tBID to cause cytochrome c release (Fig. 5g) .
To further examine whether this putative BH3 domain is required for the pro-apoptotic activity of CRK in cells, we mutated the highly conserved aspartic acid (D91A) in CRKII and evaluated the ability of this mutant to rescue the Crk −/− MEF phenotype. In comparison with wild-type Crk, the BH3 mutant Crk (D91A) has significantly decreased apoptotic activity, indicating that this region is critical for its pro-death signalling (Fig. 5h,i) .
Together, these results identify CRK as a major pro-apoptotic signal required for the execution of ER-stress-induced cell death. During ER stress, CRKI and CRKII are cleaved by a yet to be identified cysteine protease to generate an N-terminal fragment with potent apoptotic activity. Furthermore, CRK interacts with anti-apoptotic BCL-XL and its apoptotic activity is upstream of the BAX/BAK-dependent mitochondrial pathway. Both CRK isoforms contain a putative BH3 domain, which sensitizes isolated mitochondria to tBID-induced cytochrome c release and when mutated diminishes apoptotic activity in cells. These data indicate that CRK is a previously unidentified BH3-only-like protein, which following ER stress is proteolytically processed into a pro-death signal. Our findings indicate that CRK may be a valuable therapeutic target in diseases where ER-stress-induced cell loss is implicated, including some forms of neurodegeneration and diabetes 1, 2 . We have identified a previously unknown pro-apoptotic function common to both CRK isoforms. CRK was initially identified through its homology with transforming v-crk (refs 7,30,31) . However, only CRKI has been shown to have transforming activity in some cell culture models, and it is upregulated in a number of human cancers 32, 33 . Clues that CRK mediates apoptosis are present in other species. For example, the Caenorhabditis elegans CRK homologue CED-2 regulates apoptotic engulfment 34, 35 . Mammalian CRKII has been reported to induce death in some transformed cell types following overexpression 36, 37 and is required for apoptotic activity that can be detected in Xenopus egg extracts [38] [39] [40] . Our work connects CRK to apoptosis, specifically under ER stress, in mammalian cells.
In addition to the shared pro-apoptotic function we have discovered for CRKI and CRKII, there are notable and possibly functionally significant differences between the isoforms. Our inability to establish a cell line stably overexpressing CRKI, in contrast to multiple cell lines stably overexpressing CRKII, indicates that CRKI may be the more cytotoxic isoform. Indeed, the expression of endogenous CRKI is restricted to approximately 10% that of CRKII ( Supplementary Fig. S1 ), perhaps to limit its toxicity. In support of this notion, CRKI is cleaved more efficiently and earlier than CRKII in response to ER stress ( Fig. 4c and Supplementary Fig. S4 ). These observations and our discovery that CRKI can be converted into a pro-apoptotic protein in response to ER stress raise the possibility that pharmacologic inducers of ER stress may have therapeutic efficacy in cancers where CRKI is upregulated. 
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Cellular fractionation and cytochrome c release assay. MEFS were resuspended in mitochondria isolation buffer (200 mM sucrose, 10 mM Tris/MOPS (morpholinepropanesulphonic acid) (pH 7.4) and 1 mM EGTA) plus 1× protease inhibitor cocktail (Sigma) and manually disrupted by shearing the suspension 10 times through a 27-gauge and then 10 times through a 30-gauge needle. Mitochondria (heavy membrane) were isolated from the suspension with an initial centrifugation at 700×g and 4 • C to remove nuclei, followed by centrifugation at 7,000×g and 4 • C to isolate the heavy membrane (mitochondrial) fraction. The ER (light membrane) was isolated from the cytosolic fraction (S100) by centrifugation at 100,000×g and 4 • C. Mitochondrial and ER fractions were resuspended in RIPA (150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS and 50 mM Tris (pH 8.0)). S100 was dialysed for 2 h into 10% glycerolcontaining mitochondria experimental buffer (125 mM KCl, 10 mM Tris/MOPS (pH 7.4), 5 mM glutamate, 1.25 mM malate, 2 µM EGTA and 1 µM potassium phosphate). Jurkat mitochondria for the cytochrome-c-releasing assay were isolated as described above, minus the second shearing through the 30-gauge needle. For the cytochrome-c-releasing assay, 100-200 µg (sample dependent) of S100 extract was incubated with 50 µg of isolated Jurkat mitochondria for 45 min at room temperature. Following the incubation, the supernatant and pellet were separated by centrifugation at 16,000×g and 4 • C. The remaining cytochrome c was released from mitochondria by resuspending the pellet in PBS plus 0.05% Triton X-100. The amount of cytochrome c present in the supernatant and lysed pellets was quantified using a human cytochrome-c enzyme-linked immunosorbent assay (ELISA; R&D Systems) as per the manufacturer's instructions. The percentage of cytochrome c release was calculated by dividing the amount of cytochrome c present in the supernatant by the sum of cytochrome c present in both the supernatant and pellet fractions.
Purification of CcRA. The ER stress apoptotic factor was purified using the CcRA assay described above using an AKTA fast protein liquid chromatography system (GE Healthcare). Briefly, 804 mg of S100 protein isolated from 24-h-BFA (2.5 µg ml −1 )-treated Bax −/− Bak −/− MEFs was initially precipitated with 40-80% saturated ammonium sulphate. This active fraction was then further purified on a phenyl Sepharose column (GE Healthcare) by loading in 1 M ammonium sulphate and eluting with a 100 mM Na 2 HPO 4 -100 mM Na 2 HPO 4 gradient. The CcRA eluted in the 100.925-62.875 ms cm −1 range and was further purified on a Mono P column (GE Healthcare) gradient pH 6-10. The CcRA eluted between pH 9-6. This fraction was then purified further on the Superdex 200 column (GE Healthcare) and eluted in the M r 10K-44K range. This CcRA-containing-fraction was run over a Mono Q column (GE Healthcare) 10 mM KCl-1 M KCl gradient. The purified CcRA fraction was analysed in-gel and in-solution by tandem mass spectrometry by the UCSF Biomolecule Core Facility and the Stanford University of Medicine, Protein and Nucleic Acid Facility (PAN). 
